埃克替尼对血脂含量的影响:一项单中心回顾性研究

Effect of icotinib on human blood lipid contents: a single center retrospective study

目的探究酪氨酸激酶抑制剂埃克替尼对临床患者血脂的影响。方法通过回顾性分析方法收集2015年1月至2019年7月期间,于广西医科大学第一附属医院接受埃克替尼治疗的符合纳入标准且随访信息完整的36例晚期肺癌患者病历信息,将其分为4组。观察埃克替尼治疗前后血脂水平的变化。应用配对样本t检验、方差分析、卡方检验进行数据分析。结果埃克替尼治疗至少1个月(中位治疗时间[1个月,6个月])可显著降低患者血清总胆固醇(治疗前均值4.886 mmol/L,治疗后均值4.409 mmol/L,t=2.787,P<0.01)、低密度脂蛋白(治疗前均值2.957 mmol/L,治疗后均值2.53 mmol/L,t=9.596,P<0.01)和载脂蛋白B(治疗前均值1.003 mmol/L,治疗后均值0.900 mmol/L,t=2.828,P<0.01)的含量。结论埃克替尼可有效降低肺癌患者血脂含量,提示其可能用于非酒精性脂肪性肝病的降脂治疗。

Objective To explore the effect of tyrosine kinase inhibitors(TKIs)that can bind to epidermal growth factor receptor(EGFR)on blood lipid in patients.MethodsIn this study,we retrospectively reviewed medical record for patients with advanced lung cancer and treated with Icotinib,a first generation of EGFR-TKI,from January 2015 to July 2019.A total of 36 patients who had complete follow-up medical information were recruited and divided into four groups.The changes in blood lipid levels before and after treatment were evaluated.The paired sample Student’s t test,analysis of variance(ANOVA)with Bonferroni post hoc test and Chi Square test were performed for data analysis.ResultsIcotinib could significantly reduce the content of serum total cholesterol(the mean before treatment was 4.886 mmol/L,the mean after treatment was 4.409 mmol/L,t=2.787,P<0.01),low density lipoprotein(the mean before treatment was 2.957 mmol/L,the mean after treatment was 2.53 mmol/L,t=9.596,P<0.01)and Apolipoprotein B(the mean before treatment was 1.003 mmol/L,the mean after treatment was 0.900 mmol/L,t=2.828,P<0.01)after treatment with Icotinib for at least one month[duration of treatment],IQR(one month,6 months).ConclusionIcotinib can effectively reduce the lipid content of patients,suggesting that it may be used in the treatment of non-alcoholic fatty liver disease.